TUCSON, Ariz. — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that internationally renowned physician-scientist Jerald Radich, M.D., a pioneer in the fields of leukemia research and molecular genetics, has joined HTG’s Therapeutics Scientific Advisory Board. Dr. Radich adds to the company’s growing group of esteemed advisors as HTG continues to expand its therapeutics division activities targeting disruption of the existing drug discovery process.
“Dr. Radich brings an extraordinary depth of experience in the fields of cancer diagnostics and therapeutics, as well as research, to understand the basis of response versus non-response to both standard leukemia therapies and more recent molecular targeting approaches,” said Stephen Barat, Senior Vice President of Therapeutics at HTG. “We believe he will be an invaluable asset to our team as we apply our proprietary HTG Transcriptome Panel (HTP), microRNA and RNA methylation modification profiling capabilities in our goal to reveal novel factors of disease. These data are expected to be critical to identifying the pathways that mediate response and resistance to current treatment options in leukemia, specifically chronic and acute myeloid leukemias (CMLs and AMLs), and drug-independent mechanisms of resistance which result in most patients relapsing, even after initial positive responses.”
A medical oncologist specializing in the molecular genetics of leukemia and the pathways that mediate treatment response, progression and relapse, Dr. Radich holds the Kurt Enslein Endowed Chair at Fred Hutchinson Cancer Research Center (“Fred Hutch”). He is also the Director of the Molecular Oncology Lab at Fred Hutch, a global center for molecular testing for Fred Hutch researchers and clinical research centers around the world. His lab specializes in developing methods to improve the detection and treatment of CMLs and AMLs. Having led groundbreaking research in this area, Dr. Radich and his colleagues served as the U.S. and Canada reference lab for several large clinical trials of anti-CML tyrosine kinase inhibitor drugs (imatinib, dasatinib and nilotinib), all now FDA-approved for CML patients.
HTG Therapeutics is developing a suite of technologies including whole transcriptome mRNA, miRNA and RNA modification profiling, as well as an in-silico medicinal chemistry platform and advanced informatic capabilities, that are intended to deliver de-risked drug candidates with improved efficacy and reduced toxicity for either internal clinical development or out-licensing.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding HTG’s therapeutics division, its suite of technologies, activities targeting disruption of the existing drug discovery process, and its goals to reveal novel factors of disease and deliver de-risked drug candidates. Words such as “designed to,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our whole transcriptome mRNA, miRNA and RNA modification profiling technologies, medicinal chemistry platform and advanced informatics capabilities may not have the utility we expect; the risk that our therapeutics division may not reveal novel factors of disease or deliver de-risked drug candidates as expected, or at all; risks associated with the impact of the COVID-19 pandemic on us and our customers;; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the SEC on November 10, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.